Wilmington, Delaware, December 27, 2024 (GLOBE NEWSWIRE) — Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman Islands exempt company, today announced that, in order to extend the date on which the Company is expected to complete its initial business combination from December 28, 2024 to January 28, 2025, on December 27, 2024, I-Fa Chang, manager of the Company’s sponsor, has deposited into his trust account (the “Trust Account”) a total of $60,000 (the “Monthly Extension Payment”).
Pursuant to the Third Amended and Restated Memorandum and Articles of Association of the Company (“Current Charter”), effective April 23, 2024, the Company may extend on a monthly basis from April 28, 2024 to January 28, 2025 or such earlier date if may be determined by its board of directors to effect a business combination by depositing the monthly extension payment for each month into the trust account. This is the ninth of nine monthly extensions requested under the company’s current charter.
About Aimfinity Investment Corp.
Aimfinity Investment Corp. I is a blank check company incorporated as a Cayman Islands exempt company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or consolidation of similar businesses with one or more businesses or entities. The Company has not selected any business combination target and has not, nor anyone on its behalf, entered into substantial discussions, directly or indirectly, with any business combination target in connection with a first business combination businesses with her. Although the Company will not be limited to any particular industry or geographic region in its identification and acquisition of a target company, it will not complete its initial business combination with a target headquartered in in China (including Hong Kong and Macau) or which will conduct the majority of its activities in China (including Hong Kong and Macau).
Additional information and where to find it
As previously disclosed, on October 13, 2023, the Company entered into this agreement and plan of merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between the Company, Docter Inc., a Delaware corporation (the “Company”), Aimfinity Investment Merger Sub I, a Cayman Islands exempt corporation and wholly owned subsidiary of Parent (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of Buyer (“Merger Sub”), pursuant to which the Company proposes to enter into a business combination with Docter involving a reincorporation merger and a acquisition merger. This press release does not contain all of the information that should be considered in connection with the proposed business combination and is not intended to form the basis of an investment decision or any other decision relating to the business combination. businesses. AIMA shareholders and other interested persons are advised to read, when available, the proxy statement/prospectus and amendments thereto and other documents filed in connection with the proposed business combination, because these The documents will contain important information about AIMA, the buyer or Docter, and the proposed business combination. When available, the proxy statement/prospectus and other documents relevant to the proposed business combination will be mailed to AIMA shareholders on a record date to be established for voting on the proposed business combination. companies proposed. Such shareholders will also be able to obtain free copies of the proxy statement/prospectus and other documents filed with the Securities and Exchange Commission (the “SEC”), when available, on the SEC’s website at address www.sec.govor by directing a request to the AIMA main office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-looking statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements regarding the current transactions described herein and the outlook and expectations of the parties, are forward-looking statements. These statements include, but are not limited to, statements regarding the proposed transaction, including anticipated initial enterprise value and post-closing equity value, benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, future financial and operational forecasts. performance and results, including expected growth estimates, management and governance of the combined company, as well as the expected timing of transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various known and unknown risks and uncertainties, assumptions (including assumptions regarding general economic, market, industry and operational factors), which could cause actual results vary materially from those indicated or anticipated.
These risks and uncertainties include, but are not limited to: (i) risks relating to the expected timing and likelihood of consummation of the pending business combination, including the risk that the transaction may not be completed due to one or more conditions for closing the transaction. is not satisfied or waived, such as that regulatory approvals have not been obtained, timely or otherwise, or that a governmental entity has prohibited, delayed or refused to grant approval for the completion of the transaction or has required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate activities; (iii) the occurrence of any event, change or other circumstance which may give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change in the financial condition, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time of ongoing business operations due to the proposed transaction; (vi) the risk that any announcement relating to the proposed transaction may have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on Docter’s ability to retain its customers, retain and hire key personnel and maintain relationships with its suppliers and customers and on its results operating and its activities in general; (viii): risks related to the medical device industry, including, but not limited to, government changes in regulation and enforcement, market competition, competitive products and activities of pricing; and (ix) risks related to the combined company’s ability to improve its products and services, execute its business strategy, expand its customer base and maintain stable relationships with its business partners.
A more detailed list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating to AIMA’s initial public offering, AIMA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on April 17, 2023, as well as in the registration statement/proxy statement to be filed with the SEC by AIMA and/or its companies affiliates in connection with the proposed transactions, and other documents the parties may file or provide to the SEC, which you are encouraged to read. If one or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results could differ materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and Aimfinity, Docter and their affiliates undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made. been made, unless required by applicable law or regulation.
No offer or solicitation
This press release does not constitute a proxy statement or solicitation of proxy, consent or authorization with respect to any security or with respect to any potential transaction and does not constitute an offer to sell or solicitation offer to purchase any securities of AIMA, Buyer or Doctor, and there shall be no sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or release. qualification under the laws securities of that state or jurisdiction. No offer of securities may be made except by means of a prospectus meeting the requirements of the Securities Act.
Tender participants
AIMA, Docter and their respective directors, executive officers, other officers and employees, under the rules of the SEC, may be considered participants in the solicitation of proxies from AIMA’s stockholders in connection with the proposed transaction . Information regarding persons who may, under SEC rules, be considered participants in the solicitation of AIMA stockholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus on the Form F-4 which will be filed with the SEC.
Contact details:
Aimfinity Investment Corp.
I-Fa Chang
General manager
(425) 365-2933
221 West 9th Street, PMB 235
Wilmington, Delaware 19801
